Post-Marketing Surveillance (Usage Results Study) of Ixazomib Citrate in Patients With Multiple Myeloma in South Korea
Latest Information Update: 23 Jun 2022
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Takeda
- 15 Jun 2022 Planned End Date changed from 27 Sep 2023 to 27 Jun 2024.
- 15 Jun 2022 Planned primary completion date changed from 30 Jul 2023 to 27 Jun 2024.
- 27 Apr 2022 Planned End Date changed from 28 Feb 2023 to 27 Sep 2023.